For non-alcoholic fatty liver disease, SGLT2 inhibitors are more effective in reducing AST, ALT, FIB-4, PDFF, VFA, SFA, and weight levels than other antihyperglycemic drug; however, their decreasing effect on HbA1c, FPG, and HOMA-IR levels was not superior over other antihyperglycemic drugs. Here, GPT is linked to metabolic dysfunction-associated steatotic liver disease.